Social Capital Suvretta Holdings Corp. III
Completed
Follow
Detailed Information
Information on this SPAC.
- Sponsors
- IPO Size
- $200M
- Underwriters
- Focus
- Biotech
- SEC Filings
- 1850270
- Public Embarc Page
- https://embarc.com/capital/spac/1850270/DNAC/social-capital-social-capital-suvretta-holdings-corp-iii
- IPO Ticker
- DNAC
SPAC Leadership
Information on the SPAC leadership.
- Chief Executive Officer and Chairman of the Board of DirectorsChamath Palihapitiya(Managing Partner of Social Capital, Chairman of Virgin Galactic)
- PresidentKishen Mehta
- DirectorMarc Semigran(Chief Medical Officer of Renovacor)
- Chief Financial OfficerJames Ryans
- Director of ResearchShoney Katz
- President and DirectorKishan (a/k/a Kishen) Mehta
Target Information
Information on the SPAC target for merger.
- Company
- ProKidney
- Presentation
- Investor Presentation (SEC) on 2022-01-18
- New Ticker
- PROK
- Description
- ProKidney is "a leading clinical-stage cellular therapeutics company focused on chronic kidney disease."